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Abstract: In this review we consider the therapeutic potential of targeting Akt for the treatment 
of COPD. Akt is a serine/threonine protein kinase that functions as a signaling intermediate 
linked to multiple signaling programs involved in survival, inﬂ  ammation, and growth. Akt is 
closely associated with key membrane-bound receptors and represents a convergent integration 
point for multiple stimuli implicated in COPD pathogenesis. Persistent activation of Akt 
secondary to somatic mutations in regulatory oncogenes, such as PTEN, may explain why 
inﬂ  ammation in COPD does not resolve when smoking is ceased. Akt is also implicated in the 
systemic manifestations of COPD such as skeletal muscle wasting and metabolic disturbances. 
Furthermore, targeting Akt may provide a useful means of limiting the severity and duration 
of disease exacerbations in COPD. As such, Akt represents a particularly attractive therapeutic 
target for the treatment of COPD. Interestingly, current knowledge suggests that both inhibitors 
and activators of Akt may be useful for treating different clinical subpopulations of COPD 
patients.
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Chronic obstructive pulmonary disease will be the third most common cause of 
death worldwide by 2020 (Murray and Lopez 1996), and costs the global healthcare 
system tens of billions of dollars annually. For reasons that are largely unknown, 
COPD is only marginally responsive to all contemporary drugs, even powerful 
antiinﬂ  ammatory glucocorticosteroids (Keatings et al 1997; Barnes 2000). COPD is 
diverse and encompasses emphysema, the proteolytic destruction of alveolar units; 
bronchitis, associated with massive goblet cell and mucous gland proliferation; 
and bronchiolitis, an inﬂ  ammatory condition of small airways associated with 
ﬁ  broblast proliferation and ﬁ  brosis. The cause of most COPD is cigarette smoking, 
but the molecular pathogenesis of COPD is obscure. Inhaled smoke or irritants are 
thought to trigger alveolar macrophages and the epithelium to secrete tumor necrosis 
factor-alpha (TNF-α), interleukin 8 (IL-8), and chemokines such as macrophage 
inﬂ  ammatory proteins (MIPs). These factors are chemotactic and activating factors 
for neutrophils, macrophages, and other inﬂ  ammatory cells. Over time the lung also 
accumulates increased numbers of CD8+ lymphocytes, which are capable of triggering 
macrophage-dependent lung proteolysis. Emphysema results from destruction of 
alveolar units by proteases such as neutrophil elastase (NE; also a potent goblet cell 
secretagogue), macrophage metalloelastases like MMP-12 (Finkelstein et al 1995; 
Hautamaki et al 1997), and possibly also by apoptosis of alveolar wall cells.
In the small airways, ﬁ  broblast proliferation and collagen deposition cause ﬁ  xed 
airway obstruction (Hogg et al 2004). The resulting airﬂ  ow limitation is compounded 
in many patients by mucus hypersecretion and inﬂ  ammation. Lung destruction in 
COPD is well correlated with the intensity of inﬂ  ammation and once inﬂ  ammation is 
established in COPD, removing the provocative stimulus through smoking cessation 
does not resolve disease (Turato et al 1995). Furthermore, it is unknown why COPD 
is associated with a very high prevalence of both viral and bacterial exacerbations 
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(known triggers of the innate immune system, speciﬁ  cally 
macrophages and natural killer cells), prompting further 
damage to the lungs. It is believed that much of the 
deterioration that accompanies exacerbations is due to ﬂ  aring 
of inﬂ  ammation. This interpretation is supported by spikes 
in inﬂ  ammatory markers during exacerbations measured in 
sputum and in breath condensates. 
Although there remains much to be understood, our 
current understanding of molecular pathways in COPD 
pathogenesis implicates Akt as a central regulator. Akt, 
(also previously referred to as protein kinase B [PKB]), is an 
intracellular serine/threonine protein kinase that is activated 
by a broad range of cytokines (eg, TNFα) (Murao et al 2000), 
growth factors (eg, PDGF, GM-CSF, CTGF) (Klein et al 
2000; Rauch et al 2000; Crean et al 2002), and cigarette 
smoke components, including nicotine (Nakayama et al 
2002; West et al 2003). In particular, Akt is a major target of 
PI3-kinase (PI3K) dependent signaling pathways (Figure 1). 
On activation, Akt is recruited to membrane associated 
signaling complexes and activated by phosphorylation. In 
addition to Akt, PI3K activates multiple signaling kinases 
(PKC, MAPK, Btk, ILK) involved in key processes. Hence, 
targeting PI3K directly may be detrimental due to its 
pleiotropic activities.
There are three known homologs of Akt that display a 
high level of homology at the amino acid level (Table 1). 
The most characterized isoform, Akt1, is expressed in 
various tissues including lung, and targets diverse substrates 
involved in critical cellular events such as cell survival, 
proliferation, and transcription. 
Hence, the multifunctional activities of Akt have 
the potential to coordinate cellular mechanisms that are 
strongly implicated in the destructive pathogenesis of COPD 
(Figure 2). As Akt is a serine/threonine kinase it is amenable 
to selective pharmacological inhibition (Glazer 1998).
Rationale for inhibiting Akt activity 
in COPD
Role in cell survival 
Apoptosis governs the persistence and severity of 
inﬂ  ammation. Akt promotes inﬂ  ammatory cell survival in 
vivo. More speciﬁ  cally, oxidative stress and/or GM-CSF- 
mediated activation of Akt enhances cell survival of 
macrophages, neutrophils, and T lymphocytes (Jones 
et al 2000; Klein et al 2000; Wang et al 2000). Akt inhibits 
apoptosis by four main mechanisms: (1) phosphorylation 
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Figure 1 Ligand-targeted activation of Akt. Ligand-mediated activation of a broad range of receptors promotes recruitment of PI3K (p85 and p110 complex) to the plasma 
membrane, where this lipid kinase catalyzes the production of phosphatidylinositol-3,4,5-phosphate (PtIn3,4,5)-P. PTEN (lipid phosphatase) limits this reaction by reverting 
PtIns(3,4,5)-P to PtIns(3,4)-P.  This phospholipid acts as a docking molecule for both Akt and its activator PDK-1, which activates Akt by direct phosphorylation of the criti-
cal T(activation)-loop residue (Thr-308). Once active,  Akt is released from the membrane to target multiple cellular substrates and is subsequently inactivated by protein 
phosphatase2A (PP2A) dephosphorylation.
Table 1 Mammalian Akt homologs
Isoform  Homology to Akt1  Distribution
Akt1 100%  Ubiquitous
Akt 2  90%  Prominent in heart, liver, muscle,  
    kidney, and adipose tissue 
Akt 3  83%  Prominent in brain, kidney, lung,  
   testisInternational Journal of COPD 2006:1(1) 33
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and inactivation of BAD (Datta et al 1997, 1999), which 
normally binds to and inactivates antiapoptotic Bcl2 
and BclXL, a critical step in the activation of the caspase 
protease pathway. However, since Akt displays pro-survival 
properties in tissues that do not express detectable levels of 
BAD, alternative mechanisms must exist. Akt also promotes 
survival by: (2) phosphorylation of lytic pro-caspase-9 
(Cardone et al 1998). This event blocks the activity of 
pro-caspase-9 by altering the conformation of its substrate-
binding pocket, thereby inhibiting apoptosis. Apoptosis 
can also be induced by expression of key genes involved 
in cell death. For example, withdrawal of survival factors 
promotes transcription of the Fas ligand gene involved in 
positively regulating the caspase protease pathway. Akt 
controls their expression by: (3) maintaining Forkhead 
family of transcriptional factors (AFX) in a transcriptionally 
silent form (Biggs et al 1999; Brunet et al 1999). In the 
absence of Akt signaling, AFX members are directed to 
the nucleus where they bind to insulin-responsive sequence 
(Irs) found in a number of promoters responsible for 
controlling apoptosis gene expression. When Akt activity 
is maintained for prolonged periods, Forkhead members 
are sequestered away from the nucleus by Akt-mediated 
phosphorylation. Phosphorylated AFX members are 
kept transcriptionally silent due to a physical interaction 
with the structural cytoplasmic protein, 14-3-3. (4) More 
recently, Akt has been shown to promote activation of the 
transcription factor CREB, which enhances transcription of 
cell survival genes such as the Bcl-2 family member, Mcl-1 
(Wang et al 1999). Therefore, in a chronically inﬂ  amed 
COPD lung that is constantly exposed to cigarette smoke 
and airborne pathogens, Akt activity will be maintained 
for prolonged periods. The persistence of Akt-mediated 
survival of inﬂ  ammatory cells may prove to be an integral 
process responsible for the accumulation of macrophages, 
neutrophils, and T lymphocytes in the airways, parenchyma, 
and pulmonary vasculature. A paradox that cannot be 
explained with current knowledge is that the epithelium 
and T cells from COPD patients have a somewhat increased 
rate of apoptosis (Hodge et al 2005). Majo et al (2001) have 
reported enhanced parenchymal apoptosis in COPD in 
association with lymphocytic inﬁ  ltration. The increased rate 
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Figure 2  Akt is a molecular mediator of cellular processes central to COPD pathogenesis. Cell surface receptors on alveolar macrophages and the bronchial epithelium 
recognize and respond to cigarette smoke components and respiratory pathogens. These unique signaling modules converge onto and activate multiple pathways including 
Akt. Once active, Akt contributes to key cellular processes including proliferation, apoptosis, and inﬂ  ammation. Therefore, dysregulated activation of Akt in a chronically 
inﬂ  amed environment has the potential to disrupt homeostasis, leading to an altered pathology responsible for dramatic and progressive decline in lung function. International Journal of COPD 2006:1(1) 34
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of apoptosis needs to be balanced against evidence for 
enhanced proliferation (Yokohori et al 2004). Tomita and 
colleagues (2002) found that alveolar macrophage apoptosis 
was decreased in macrophages from smokers in association 
with increased p21(Cip/Waf) BCLxL expression. Neutrophil 
apoptosis is markedly reduced during COPD exacerbations 
(Pletz et al 2004). It has also been suspected for some time 
that vascular endothelial cell death may be a pathogenic 
contributor to the development of emphysema in COPD 
(Kasahara et al 2000).
Role in proliferation 
Akt may promote in situ macrophage and fibroblast 
proliferation. Macrophage proliferation in COPD has been 
recognized for several decades (Bitterman et al 1984) 
notwithstanding recent evidence suggesting increased 
apoptotic rates. Most in vitro evidence suggests that smoke 
directly suppresses ﬁ  broblast proliferation in COPD but the 
pattern of growth factor expression in thickened small airways 
suggests the opposite occurs in vivo. The in vivo response 
of parenchymal ﬁ  broblasts is less certain. Macrophage and 
ﬁ  broblast proliferation in COPD worsens inﬂ  ammation and 
promotes airway ﬁ  brosis, which leads to ﬁ  xed obstruction 
in small airways. Inhaled smoke and pathogen products 
released during exacerbations cause lung tissue damage, 
which triggers tissue repair mechanisms releasing multiple 
growth factors including PDGF, TGFβ, IGF1, EGF, CTGF, 
and bFGF, all of which activate Akt. 
Recently, Akt has been implicated in the regulation 
of cellular proliferation and cell cycle control, a function 
more usually associated with MAP kinases. Akt inactivates 
the cell cycle regulator GSK3 by phosphorylation (Shaw 
et al 1997), promoting cell cycle entry by targeting D-type 
cyclins for proteolysis (Diehl et al 1998). Hence, mitogen-
induced activation of cyclin D ultimately leads to the G1➝S 
transition of the cell cycle. Furthermore, by phosphorylating 
and inactivating AFX transcription factor, Akt also blocks 
expression of the cell cycle inhibitor p27kip1, whose expression 
is AFX dependent (Medema et al 2000). This prevents p27kip1 
from binding to the cyclinD/CDK2 complex and derepressing 
cell cycle arrest.
Role in inﬂ  ammation 
Akt is directly activated by gram-negative bacterial cell wall 
lipopolysaccharide (LPS) (Bozinovski et al 2002, 2004) 
and other innate immunity triggers implicated in COPD 
exacerbations (Salh et al 1998). In addition, Akt is activated 
by oxidative stress, in part via the EGF receptor (EGFR) 
(Wang et al 2000), both of which are strongly implicated 
in COPD (MacNee 2000). Akt selectively triggers NFκB 
p65/RelA heterodimer activation to coordinate monocyte and 
neutrophil recruitment in response to smoke and infection. 
The transduction pathways and inﬂ  ammatory responses 
activated by cigarette smoke and infectious pathogen 
products such as LPS trigger innate immunity-mediated 
exacerbations in a similar manner, as inferred by coordinated 
expression of chemoattractant factors following activation of 
NFκB. This is not just because LPS is a biologically active 
component of cigarette smoke occurring in concentrations 
known to cause lung disease (Hasday et al 1999). It is also 
because cigarette smoke consists of multiple components 
capable of stimulating signal transduction pathways that are 
similar to those triggered by receptors of the innate immune 
system. Bacterial endotoxins stimulate lung epithelial cells 
to release neutrophil and monocyte chemotactic peptides 
(Koyama et al 1999, 2000) by coordinated activation of Toll-
like receptors (TLRs) that respond to LPS (gram-negative cell 
wall component; TLR4) and lipoteichoic acid (gram-positive 
cell wall component; TLR2) (Brightbill et al 1999; Takeuchi 
et al 1999; Underhill et al 1999). Consistent with LPS, 
cigarette smoke extract also promotes release of chemotactic 
factors (Masubuchi et al 1998). Binding sites for NFκB 
are present in the promoter region of many inﬂ  ammatory 
mediators including GM-CSF (Thomas et al 1997), MCP-1 
(Takaya et al 2000), and IL-8 (Ozes et al 1999); and NFκB 
cooperates as part of a higher order complex to promote 
transcription. NFκB is normally sequestered in the cytoplasm 
through an association with inhibitor of NFκB (IκB). When 
cells are exposed to activation signals such as LPS, oxidative 
stresses, and TNFα, IκB is phosphorylated and targeted for 
proteolytic destruction. This process is promoted by Akt, 
which triggers IκB kinase alpha (IKKa) to phosphorylate IκB 
(Ozes et al 1999). Akt can also enhance the DNA binding 
activity of NFκB by targeting the transactivation domain of 
the p65 subunit for phosphorylation (Sizemore et al 1999; 
Madrid et al 2000).
Akt, lung cancer, and acquired somatic 
mutations of the lung epithelium 
Lung cancer is the most frequent cause of tumor-associated 
deaths in the US and is strongly associated with chronic 
smoking. Lung cancer arises from a series of pathological 
changes linked to both gross genetic alterations and quite 
discrete acquired gene changes known as somatic mutations. 
Airﬂ  ow obstruction is commonly present in patients with 
bronchial carcinoma (Congleton and Muers 1995), and International Journal of COPD 2006:1(1) 35
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the presence of moderate to severe airﬂ  ow obstruction is a 
signiﬁ  cant predictor of incident lung cancer (Mannino et al 
2003). Therefore, a logical and widely accepted corollary is 
that chronic inﬂ  ammation predisposes to the development 
of cancer (Marx 2004). Since the acquisition of somatic 
mutations predisposes to lung cancer, we have previously 
proposed that non-inherited genetic abnormalities also 
contribute to the pathogenesis of COPD (Anderson and 
Bozinovski 2003). As only 15% of smokers develop COPD, 
much recent research has focused on identifying inherited 
genetic risk factors such as α1-antitrypsin deficiency 
associated with early onset COPD. However, less then 1% 
of COPD patients display α1-antitrypsin deﬁ  ciencies, and 
searches for other heritable mutations including TNFα, 
IL-10, MMPs, and IL-8 have yielded limited success. We 
have proposed the novel hypothesis that a fundamental 
determinant of COPD is the acquisition of mutations (caused 
by mutagens in cigarette smoke) in regulatory oncogenes 
that control Akt activation status in the epithelium. This 
hypothesis is supported by cytogenetic studies on the 
molecular pathogenesis of lung cancer that have unequiv-
ocally demonstrated very frequent loss of heterozygosity 
(LOH) somatic mutations in preneoplastic/dysplastic 
epithelium of smokers (Wistuba et al 1997; 2002). 
Indeed it is now apparent that the epithelium can become 
a mosaic of epithelial lineages, each carrying one or more 
somatic mutations. Although histological abnormalities 
in the epithelium associated with smoking can resolve 
after cessation, these somatic mutations persist as much as 
inﬂ  ammation persists in the mucosa of ex-smokers (Wistuba 
et al 1997). Multiple gene mutations appear necessary to 
develop lung cancer, but single gene loci changes may 
be sufﬁ  cient to trigger COPD. Of the known oncogenic 
mutations in the epithelium, three of the most frequent 
directly promote Akt activation. These are: (1) oncogenic 
mutations of Ras (p21); a GTP bound form of Ras interacts 
with PI3K, that in turn activates Akt. Ras mutations occur 
in approximately 30% of all human malignancies with 
a >30% mutation frequency in the bronchial epithelium 
of human lung cancer patients (Scott et al 1997). Ras-
transformed adherent epithelial cells display elevated levels 
of Akt activity, and inhibition of this activity blocks the 
transforming potential of Ras by inducing cell death (Khwaja 
et al 1997). (2) The lipid phosphatase tumor suppressor 
PTEN degrades phospholipid products generated by PI3K, 
thereby negatively regulating the activity of Akt. PTEN is 
mutated in a large fraction of all human cancers, with a 
mutation frequency approaching that of p53. More recently, 
PTEN mutations have been found in 6/15 (40%) of small 
cell lung carcinomas (SCLC) (Kohno et al 1998). Loss of 
PTEN activity attributed to homozygous deletions of the 
PTEN gene correlate with elevated levels of Akt activity, 
and reconstitution of PTEN restores normal Akt regulation 
(Stambolic et al 1998). (3) A constitutively active form of 
PI3K has been reported to exist in a small-scale screen of 
SCLC cell lines. Of the ﬁ  ve cell lines tested, all exhibited high 
basal constitutive PI3K activity, which resulted in elevated 
basal Akt activity (Moore et al 1998).
Preneoplastic changes also occur more commonly in 
smokers and may manifest as a phenotypic abnormality in 
the bronchial epithelium known as squamous metaplasia. 
Here, ciliated epithelial cells that normally trap and remove 
airborne particulates and mucus are replaced by ﬂ  at, non-
ciliated cells. The consequences of this altered phenotype 
are believed to include airway obstruction mediated by 
mucus accumulation. In addition, impaired pathogen 
clearance has been implicated in lower airway bacterial 
colonization and is prominent in advanced COPD. The 
mechanism that drives this altered phenotype is obscure 
and thought to be associated with an ongoing damage/
repair cycle triggered by chronic smoking; however,  Akt 
may prove to be an important molecular regulator of this 
process. Conceptually, sustained activation of Akt in the 
bronchial epithelium as a consequence of exposure to 
cigarette smoke favors an ongoing proliferative process 
that prevents differentiation into normal epithelial cells. 
Consistent with this hypothesis, nicotine has been shown 
to modulate the phenotype of normal airway epithelial cells 
via an Akt dependant mechanism (Nakayama et al 2002; 
West et al 2003). 
Rationale for selective restoration 
of Akt activity in COPD
Akt and apoptosis-mediated emphysema 
The long-standing paradigm for alveolar septal wall 
destruction in emphysema involves an imbalance between 
proteases and antiproteases that results in digestion of 
elastin and other structural proteins. However, alternate 
mechanisms may also exist as alveolar matrix destruction 
is not prevalent in cystic ﬁ  brosis, acute asthma, and other 
lung diseases associated with excessive inﬂ  ammation and 
proteolysis. A recent model for the loss of lung tissue in 
emphysema implicates enhanced apoptosis as supported 
by animal models and a small number of human studies. 
Targeting disruption of vascular endothelial growth factor 
(VEGF) in mice results in increased alveolar and bronchial International Journal of COPD 2006:1(1) 36
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cell apoptosis, airspace enlargement, and persistent changes 
in lung elastic recoil (Tuder et al 2000, 2003; Tang et al 
2004). Akt plays a critical role in VEGF-mediated cell 
survival (Gerber et al 1998) and, hence, would most likely 
prevent apoptosis in VEGF depleted lungs, although this 
hypothesis has yet to be tested. Even though these ﬁ  ndings 
are quite striking in animal models, the role of VEGF in 
human COPD disease has not been clearly established. 
Despite there being no strong evidence implicating a defect 
in VEGF expression in emphysema, oxidative stress has 
been shown to impair VEGF survival signaling via inhibition 
of PI3K/Akt (el-Remessy et al 2005). More recently, 
marked alveolar apoptosis has been observed in end-stage 
emphysema patients (Yokohori et al 2004; Calabrese et al 
2005). Selective restoration of Akt in VEGF dependent 
endothelial lung cells would therefore prevent accelerated 
alveolar apoptosis associated with cellular destruction in 
emphysema.
Akt and muscle wasting in COPD 
COPD elicits a persistent local inﬂ  ammatory process that 
has quite marked peripheral consequences such as the 
wasting syndrome seen in advanced COPD. In COPD, even 
clinically obese patients have loss of lean muscle mass 
identiﬁ  ed on MRI imaging. Locally, cytokines such as IL-6, 
TNFα, and IL-1β are released in chronically inﬂ  amed COPD 
lungs, which can act on multiple organ systems, tissues, 
and cell types. Such inﬂ  ammatory cytokines are known to 
impair activity of anabolic hormones such as insulin growth 
factor-1 (IGF-1) (Spate and Schulze 2004). Akt is activated 
by IGF-1, an important mediator of signaling programs in 
skeletal muscle. For instance, increasing Akt activation 
has the potential to induce hypertrophic pathways while 
repressing atrophic processes (Bodine et al 2001; Rommel 
et al 2001). Akt promotes skeletal muscle hypertrophy 
via a number of downstream signaling pathways; direct 
and indirect targets include the mammalian target of 
rapamycin (mTOR), p70 S6 kinase (p70S6K), PHAS-1 
(4EBP-1), and glycogen synthase kinase 3β (Glass 2003). 
Reduced IGF-1 expression is observed in most wasting 
syndromes (Spate and Schulze 2004), which will impact 
on Akt activity in muscle tissue. In rodents, selective 
overexpression of Akt1 in skeletal muscle cells causes 
hypertrophy and protects against denervation-induced 
atrophy, while mice with genetically disrupted Akt1 display 
growth defects (Chen et al 2001). Thus, the IGF-1/Akt 
signaling pathway provides a potential therapeutic target for 
promoting muscle hypertrophy in chronic diseases where 
wasting manifests. However, since Akt is ubiquitously 
expressed and promotes cell survival, proliferation, and 
inﬂ  ammation, selective targeting of Akt in affected tissue 
would be most efﬁ  cacious. 
Summary
COPD is a heterogenous disease that is pathologically 
diverse, complex in nature, and is associated with defects 
in cell growth, survival, and inﬂ  ammation. Consequently, 
developing an effective therapeutic strategy is difﬁ  cult 
as multiple cellular processes need to be targeted. 
Dysregulation of Akt activity will impact on all these 
essential cellular processes, therefore implicating Akt as 
an attractive therapeutic target. The strategy of modulating 
Akt activity will develop as our understanding of COPD 
pathogenesis progresses, since there is evidence for either 
inhibiting or restoring Akt activity. The signiﬁ  cance of 
Akt will become more apparent as we evolve a better 
understanding of the cellular processes that drive the 
altered phenotype that leads to reduced lung function. The 
challenge that lies ahead is that of generating highly speciﬁ  c 
therapies that either block or restore Akt activity in discrete 
tissue compartments.
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